

patients with thrombosis tested antibody positive, compared with 26 (6.1%) of 425 patients without thrombosis (odds ratio [OR], 15.3 [95% CI, 2.94-25.23]; $P = .005$). This supports previous suggestions⁶ that formation of platelet-activating HIT antibodies can be associated with thrombosis even in the absence of a significant platelet count fall. Second, among the 87.7% of study patients who underwent serologic testing for HIT antibodies, there was approximately a 60% lower seroconversion rate with LMWH compared with UFH (55.6% and 64.7% by the platelet activation assay and immunoassay, respectively). Nevertheless, despite this moderate reduction in frequency of HIT antibody formation, there was complete avoidance of clinical HIT using LMWH (0 versus 12 cases). This underscores the importance of considering HIT to be a largely preventable adverse drug reaction, at least in postorthopedic surgery patients.

Andreas Greinacher, Petra Eichler, Theresia Lietz, and Theodore E. Warkentin

Correspondence: Andreas Greinacher, Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Armdt University, Sauerbruchstraße, 17489 Greifswald, Germany; e-mail: greinach@uni-greifswald.de

References

1. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*. 2001;344:1286-1292.
2. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med*. 1995;332:1330-1335.
3. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. *Thromb Haemost* 1991; 66:734-736.
4. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. *J Lab Clin Med*. 2001;138:22-31.
5. Ganzer D, Gutezeit A, Mayer G. Gefahrenpotentiale in der medikamentösen thromboseprophylaxe-niedermolekuläre heparine versus standardheparin. *Z Orthop Ihre Grenzgeb*. 1999;137:457-461.
6. Hach-Wunderle V, Kainer K, Krug B, Mueller-Berghaus G, Poetsch B. Heparin-associated thrombosis despite normal platelet counts [letter]. *Lancet* 1994;344:469-470.

To the editor:

A Portuguese patient homozygous for the -25G>A mutation of the *HAMP* promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron

Mutations of hepcidin are a rare cause of juvenile hemochromatosis (JH). We report a homozygous -25G>A mutation in the hepcidin 5' untranslated region (UTR) that generates a new start codon with a consequent frameshift. In this patient with a rare coincidental association of JH, Turner syndrome, and absolute lymphopenia, the absence of normal hepcidin synthesis was expected. Surprisingly, the patient had detectable hepcidin, suggesting that the start of translation was maintained at the original ATG with some normal protein production. However, hepcidin was not appropriately induced by an iron challenge test, supporting role of hepcidin on the clinical expression of iron overload in this case.

The hepatic peptide hepcidin is a key regulator of iron balance.¹ Mutations of hepcidin are a rare cause of juvenile hemochromatosis (JH),²⁻³ and include nonsense, frameshift,² and missense mutations C70R and C78T affecting conserved cysteines.³⁻⁵

Recently a -25G>A mutation in the *HAMP* 5'UTR was described in 2 Portuguese siblings with iron overload and absence of urinary hepcidin.⁶ Here, the same mutation was found in a different Portuguese family where the proband shows coincidental association of JH, Turner syndrome, and absolute lymphopenia.⁷ Although no comparative haplotype analysis was performed, geographic and historical tracking does not indicate any relationship with the previously described family. In the proband, no mutations in the coding regions of *HAMP* and hemojuvelin genes were found by sequencing.^{3,8} However, in the 5'UTR region of *HAMP*, a G>A point mutation was identified at position -25 from the canonical ATG. This was confirmed by WAVE (Transgenomic, Omaha, NE) denaturing high-performance liquid chromatography (DHPLC; heteroduplexes were formed by heat denaturation at 94°C for 3 minutes and cooling to 25°C for 45 minutes; the mixture was analyzed at a melting temperature of 64.1°C, with a linear acetonitrile gradient: Start: 44.3% Buffer A, 55.7% Buffer B; Stop: 35.3% Buffer A, 64.7% Buffer B). In a family study performed with written informed consent, both parents and one brother were heterozygous for the mutation. Elevated serum ferritin levels in these subjects were likely due to the additional effect of regular high alcohol intake.

The G>A substitution changes GTG to ATG and creates a new start site for translation. Since this mutation introduces an earlier initiation codon with a shifted reading frame, it would be expected to encode a different peptide. Surprisingly, urinary hepcidin, analyzed in first morning voided samples,⁹ was detected in the proband at a concentration of 12 ng/mg creatinine with a serum ferritin concentration of 19 ng/mL at the time of evaluation. The result was confirmed by Western blot analysis. The production of hepcidin could be explained by the maintenance of the start of translation at the original ATG, a phenomenon also observed with other genes.¹⁰ In this case, urinary hepcidin was evaluated when iron depletion had been already achieved by phlebotomy treatment. To explain the initial severe phenotype of the patient, we hypothesized that hepcidin was not appropriately induced by iron and performed an iron challenge test with urinary hepcidin determination 24 hours after the ingestion of 80 mg iron as ferrous sulfate.⁹ No increase in urinary hepcidin was observed in the patient, in contrast with a 2- to 3-fold increase observed in 2 control subjects (Figure 1). Of interest, a reduction in serum




Figure 1. Urinary hepcidin levels in 2 controls and the proband, before and after ingestion of 80 mg iron as ferrous sulfate. Synthetic hepcidin standards (20, 50, and 100 ng) and urinary extracts equivalent to 0.5 mg creatinine were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting with rabbit anti-human hepcidin antibody. 0 = urine collected before iron ingestion; Fe = urine collected 24 hours after iron ingestion. Measures of urinary hepcidin, serum transferrin saturation, and serum ferritin are given for each subject at the indicated test times.

transferrin saturation was observed in controls 24 hours after the iron challenge (Figure 1). In contrast, the transferrin saturation in the patient increased with the iron challenge. We interpret the late reduction of transferrin saturation in the controls as a delayed effect of hepcidin increase. The lack of this response in the patient supports the notion that defective hepcidin regulation played a role in her iron overload.

Graça Porto, Antonella Roetto, Filomena Daraio, Jorge Pereira Pinto, Susana Almeida, Conceição Bacelar, Elizabeth Nemeth, Tomas Ganz, and Clara Camaschella

Correspondence: Graça Porto, ICBAS, Abel Salazar Institute for the Biomedical Sciences, 4100, Porto, Portugal; e-mail: gporto@ibmc.up.pt

Partially supported by Telethon, Rome and Ministero dell'Istruzione, dell'Università e della Ricerca, Fondo per gli Investimenti della Ricerca di Base (MIUR FIRB) to C.C.; and the Gulbenkian Foundation and the Portuguese Foundation for Science and Technology (FCT).

The authors wish to acknowledge nurse Graça Melo for her work on the recruitment, organization, and collection of samples for the family study.

References

1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood*. 2003;102:783-788.
2. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. *Nat Genet*. 2003;33:21-22.

3. Roetto A, Daraio F, Porporato P, et al. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). *Blood*. 2004;103:2407-2409.
4. Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T>C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. *Hum Mutat*. 2004;4:400.
5. Delatycki M, Allen K, Gow P, et al. A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant hemochromatosis. *Clin Genet*. 2004;65:378-383.
6. Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'UTR of the HAMP gene. *Blood*. 2004;104:2181-2183.
7. Porto G, Cruz E, Pessegueiro Miranda H, et al. Growth hormone (GH)-induced reconstitution of CD8+ CD28+ T lymphocytes in a rare case of severe lymphopenia associated with juvenile hemochromatosis and Turner's syndrome. *Clin Endocr*. 2004;61:437-440.
8. Lanzara C, Roetto A, Daraio F, et al. The spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. *Blood*. 2004;103:4317-4321.
9. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest*. 2004;113:1271-1276.
10. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. *Blood*. 1998;6:2010-2014.

To the editor:

CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood

CD146, also known as S-endo-1, P1H12, Mel-CAM, and MUC18, is a well-described adhesion marker of endothelial cells, which has also been identified on a limited number of other cell types, but not in fresh peripheral blood lymphocytes from healthy individuals.^{1,2} Due to its presumed specificity, the expression of CD146 has been used as the sole criterion to identify circulating endothelial cells (CECs), and has been widely used to isolate these cells from peripheral blood (reviewed in Blann et al³ and Khan et al⁴). In contrast, our flow cytometric studies of peripheral blood have routinely detected CD146⁺ leukocytes.

In fresh peripheral blood specimens from 10 healthy individuals stained with a panel of monoclonal antibodies to leukocyte antigens and analyzed by flow cytometry, CD45⁺ CD146⁺ cells were consistently identified as 1% or less of the mononuclear cells. Table 1 and Figure 1 illustrate the expression of CD146 found on lymphoid subsets. Phycoerythrin-conjugated CD146 (clone p1H12) obtained from Becton Dickinson Biosciences (San Jose, CA) and from Chemicon (Temecula, CA) yielded similar results.

The CD3, CD146⁺ cells also expressed CD2, CD5, and CD7, confirming that these cells were T lymphocytes. The use of pulse width measurements eliminated the possibility that these cells were doublets of CECs and T cells, and the use of a viability stain (7-aminoactinomycin D [7-AAD]), as well as isotype controls, excluded the possibility that this staining was due to nonspecific

binding of the monoclonal antibodies. Washing peripheral blood mononuclear cells, as well as whole peripheral blood, with phosphate-buffered saline (PBS) twice prior to staining revealed no change in the percentage of T cells positive for CD146 or in the intensity of CD146 staining, thus eliminating the possibility that the lymphoid CD146 was due to binding of soluble CD146.




Figure 1. Freshly drawn peripheral blood stained with CD146 and antibodies to various markers for lymphocyte subsets. Using forward and side light scatter, a gate was set around the lymphoid region. A second gate was set to exclude any dead cells displaying 7-AAD staining, and a third gate based on pulse width was set to exclude doublets. All of these histograms were gated on these 3 gates. Additionally, the CD4 and CD8 histograms were also gated on the CD3⁺ cells. (A) CD3 versus CD146; (B) CD19 versus CD146; (C) CD4 versus CD146; and (D) CD8 versus CD146. Arrows indicate CD146⁺ lymphocyte subsets.

Table 1. Mean percentage of each lymphocyte subset that expresses cell surface CD146 (from peripheral blood of 10 healthy individuals)

Lymphocyte subset	Mean ± SD, %
CD3 ⁺ T cells	2.09 ± 0.84
CD3 ⁺ CD4 ⁺ T cells	2.08 ± 0.73
CD3 ⁺ CD8 ⁺ T cells	2.50 ± 2.47
CD19 ⁺ B cells	0.74 ± 0.86
CD3 ⁻ NK cells	0.11 ± 0.13